ArticleAntimicrobial agents and chemotherapy2012
Antimicrobial-resistant strains of Clostridium difficile from North America.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- The prevalence of antibiotic-resistant Clostridium species in Iran: a meta-analysis.Pathogens and global health · 2019Pooled it
- A severe Clostridioides difficile ribotype 027 infection in Beijing, China, july 2024.BMC infectious diseases · 2025Article
- Flagellar switch inverted repeats impact heterogeneity in flagellar gene expression and thus C. difficile RT027/MLST1 virulence.Cell reports · 2025Article
- Characterization of Adult and Pediatric Healthcare-Associated and Community-Associated Clostridioides difficile Infections, Canada, 2015-2022.Emerging infectious diseases · 2025Article
- The Global Burden ofInfectious disease reports · 2025Review
- Current and Ongoing Developments in TargetingMicroorganisms · 2024Review
- Antibiotic Resistances of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- Characterization of Food ChainMicroorganisms · 2023Article
- Systematic Review and Meta-Analysis on the Frequency of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- Genetic Relatedness of 5-Year Isolates ofAntibiotics (Basel, Switzerland) · 2021Article
- Diagnostic deficiencies ofSaudi journal of biological sciences · 2021Article
- A multisite genomic epidemiology study ofMicrobial genomics · 2021Article
- Inhibition of Quinolone- and Multi-Drug-Resistant Clostridioides Difficile Strains by Multi Strain Synbiotics-An Option for Diarrhea Management in Nursing Facilities.International journal of environmental research and public health · 2021Article
- Biographical Feature: Fred C. Tenover, Ph.D., D(ABMM), F(AAM), FIDSA.Journal of clinical microbiology · 2021Article
- Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes.Scientific reports · 2020Article
- Lipid Species in the GI Tract are Increased by the Commensal FungusJournal of fungi (Basel, Switzerland) · 2020Article
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014-2018.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2020Article
- Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study.Infection · 2020Article
- High Prevalence of Multidrug-ResistantFrontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 316 toxigenic Clostridium difficile clinical isolates of known PCR ribotypes from patients in North America were screened for resistance to clindamycin, metronidazole, moxifloxacin, and rifampin. Clindamycin resistance was observed among 16 different ribotypes, with ribotypes 017, 053, and 078 showing the highest proportions of resistance. All isolates were susceptible to metronidazole. Moxifloxacin resistance was present in >90% of PCR-ribotype 027 and 053 isolates but was less common among other ribotypes. Only 7.9% of the C. difficile isolates were resistant to rifampin. Multidrug resistance (clindamycin, moxifloxacin, and rifampin) was present in 27.5% of PCR-ribotype 027 strains but was rare in other ribotypes. These results suggest that antimicrobial resistance in North American isolates of C. difficile varies by strain type and parallels rates of resistance reported from Europe and the Far East.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.